Takeda: Rusfertide shows promise in polycythemia vera trial

Takeda Pharmaceutical and Protagonist Therapeutics today announced positive topline results from the Phase 3 VERIFY trial of rusfertide in patients with polycythemia vera (PV). The study met its primary endpoint, with 77% of patients on rusfertide achieving clinical success, compared to 33% on placebo (p<0.0001). A key secondary endpoint for EU regulators was also met, with rusfertide patients requiring significantly fewer phlebotomies (0.5 vs. 1.8 for placebo; p<0.0001).